comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Risk of major adverse events stroke associated treatment with or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis Cardiovascular Effects and Tolerability of
Description
ROS: reactive oxygen species
How may GIP Enhance the therapeutic efficacy of GLP-1
INTERHEART Study Investigators
Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments
Approval for treatment is not guaranteed
Evidence suggests that GLP-1s are not only effective in preventing the accumulation of amyloid beta, a protein commonly associated with Alzheimer's, but also in mitigating the hyperphosphorylation and aggregation of tau, another critical protein in the disease's progression
